- Home
- SLXN vs KAVL Comparison
SLXN vs KAVL Comparison
Compare SLXN & KAVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLXN
- KAVL
- Stock Information
- Founded
- SLXN 2008
- KAVL 1998
- Country
- SLXN Israel
- KAVL United States
- Employees
- SLXN N/A
- KAVL N/A
- Industry
- SLXN
- KAVL Medicinal Chemicals and Botanical Products
- Sector
- SLXN
- KAVL Health Care
- Exchange
- SLXN NYSE
- KAVL Nasdaq
- Market Cap
- SLXN 6.9M
- KAVL 7.9M
- IPO Year
- SLXN N/A
- KAVL N/A
- Fundamental
- Price
- SLXN $0.92
- KAVL $0.60
- Analyst Decision
- SLXN Strong Buy
- KAVL
- Analyst Count
- SLXN 1
- KAVL 0
- Target Price
- SLXN $5.00
- KAVL N/A
- AVG Volume (30 Days)
- SLXN 3.6M
- KAVL 58.0K
- Earning Date
- SLXN 05-13-2025
- KAVL 06-17-2025
- Dividend Yield
- SLXN N/A
- KAVL N/A
- EPS Growth
- SLXN N/A
- KAVL N/A
- EPS
- SLXN N/A
- KAVL N/A
- Revenue
- SLXN N/A
- KAVL $3,877,695.00
- Revenue This Year
- SLXN N/A
- KAVL N/A
- Revenue Next Year
- SLXN N/A
- KAVL N/A
- P/E Ratio
- SLXN N/A
- KAVL N/A
- Revenue Growth
- SLXN N/A
- KAVL N/A
- 52 Week Low
- SLXN $0.21
- KAVL $0.46
- 52 Week High
- SLXN $13.56
- KAVL $8.37
- Technical
- Relative Strength Index (RSI)
- SLXN N/A
- KAVL 57.65
- Support Level
- SLXN N/A
- KAVL $0.59
- Resistance Level
- SLXN N/A
- KAVL $0.65
- Average True Range (ATR)
- SLXN 0.00
- KAVL 0.04
- MACD
- SLXN 0.00
- KAVL 0.01
- Stochastic Oscillator
- SLXN 0.00
- KAVL 71.86
About SLXN BIOMOTION SCIENCES
Silexion Therapeutics Corp a clinical-stage, oncology-focused biotechnology company engaged in the discovery and development of proprietary treatments for KRAS-driven cancers. The KRAS gene is an oncogene that is involved in the regulation of cell division as a result of its ability to relay external signals into the cell. Its product candidate, SIL204, consists of locally administered small interfering RNAs, or siRNA, in a solution, as a first-line treatment of locally advanced pancreatic cancer patients, or LAPC, in combination with standard-of-care chemotherapy. It is currently focused on treatment for pancreatic cancer tumors bearing the KRAS G12D or KRAS G12V mutations where metastases have not been detected and are non-resectable, i.e. it is not able to be surgically removed.
About KAVL Kaival Brands Innovations Group Inc.
Kaival Brands Innovations Group Inc is focused on growing and incubating innovative and profitable products. The company is engaged in the sale, marketing and distribution of electronic nicotine delivery system (ENDS) products and related components. Its primary product includes Bidi Stick. The BIDI Stick comes in a variety of flavor options for adult cigarette smokers.